May 29, 2024 12:08 PM EDT

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Lia DeGroot

The FDA approved Amgen’s monoclonal antibody Bkemv as the first interchangeable biosimilar for Alexion’s blockbuster Soliris to treat two types of rare blood diseases, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Lia DeGroot

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Immunology biotech Alumis secures $250M in shrunken IPO

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Am­gen nabs FDA ap­proval for first Soliris in­ter­change­able biosim­i­lar

Lia DeGroot

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Amgen nabs FDA approval for first Soliris interchangeable biosimilar

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Immunology biotech Alumis secures $250M in shrunken IPO

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing